Prokidney (PROK) Stock Price

Prokidney Price

NASDAQ·CLOSED
1.08
​
Market closed

Prokidney's net margin stands at -7,725.2%, up from -80,507.9% several years earlier.

Prokidney stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Prokidney business model & stock analysis

Prokidney Corp, based in Winston-Salem, North Carolina, is a clinical-stage biotechnology company focused on developing cell therapy platforms for chronic kidney diseases. The company employs 231 people and is listed on the stock market since June 30, 2021. Its lead product, Renal Autologous Cell Therapy (REACT), uses a patient's own kidney cells to preserve kidney function in chronic kidney disease patients. REACT is currently in global Phase 3 trials and multiple Phase 2 trials for diabetic kidney disease.

Frequently asked questions about Prokidney

13 analysts currently rate the Prokidney stock: 9 recommend buying, 3 holding and 1 selling. For 2026, analysts expect Prokidney to generate revenue of 529,000.00 USD and earnings per share of -0.52 USD.

Converted at the current exchange rate, the Prokidney share trades at 0.97 EUR (1.08 USD).

The Prokidney share (PROK) is listed on 1 stock exchanges, including: NASDAQ (PROK).

The expected revenue of Prokidney is 529,000.00 USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Prokidney is -72.61 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Prokidney is currently -2.09. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Prokidney stock.

The price-to-sales ratio (P/S) of Prokidney is currently 286.73. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Prokidney stock.

The Eulerpool Quality Score for Prokidney is 2/10.

The ISIN of Prokidney is US74291D1046. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Prokidney is PROK. The ticker symbol is used to trade Prokidney shares on the stock exchange.

Fair ValueTerminal
0.92 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
3,865.80 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Jun 30, 2021
ISIN
US74291D1046
Cusip
G7S53R104
Market capitalization
324.90 M USDSmall Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-2.09
P/Ee 2027
-0.73
P/Ee 2028
-1.32
P/Ee 2029
-1.78
P/Ee 2030
14.73
P/Se
286.73
EV/EBIT
—
P/B Ratio
12.07
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
6.83 %
Last updated Nov 8, 2026, 2:04 PM

Prokidney Peer Group

Prokidney Ticker

NASDAQ · PROK

All fundamentals and in-depth analysis of Prokidney

Our stock analysis for Prokidney stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Prokidney. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.